Our Subsidiaries
3Sixty Global Solutions Group, a prominent medical technology company, oversees diverse subsidiaries. Founded in 2019, 3Sixty Biomedicine offers innovative solutions spanning funeral, financial, healthcare, scientific, tech, and client services. It acquired Troy Pharmaceuticals, adding herbal medicine production to its portfolio. 3Sixty Biopharmaceuticals, a SAHPRA-licensed pharmaceutical company, collaborates with global partners and maintains a robust Clinical Research & Development pipeline. 3Sixty Nuclear Medicine, provides patients access to cutting-edge radiopharmaceutical therapies and treatments. Our aim is to collaborate with reputable partners in the nuclear medicine value chain both locally and globally, so that we can improve patients lives. Cape Sativa, a subsidiary, specializes in enhancing the solubility of cannabinoids for various applications. Additionally, 3Sixty Health, founded in 1978, continues its mission to provide accessible healthcare to disenfranchised black South Africans.
Biotechnology & Health Services
3Sixty Biomedicine
3Sixty Biomedicine, under 3Sixty Global Solutions Group (formerly 3Sixty Financial Services Group), operates across funeral, financial, healthcare, scientific, tech, and client services. Evolving from Doves Group, the conglomerate expanded into finance and biotechnology. Established in 2019, 3Sixty Biomedicine offers market products with a robust pipeline. Acquiring Troy Pharmaceuticals added a Kwa-Zulu Natal-based herbal medicine manufacturer. Affiliated with 3Sixty Biopharmaceuticals, the company tackles South Africa’s healthcare challenges with innovative allopathic solutions for issues like infectious diseases.
3Sixty Biopharmaceuticals
3Sixty Biopharmaceuticals is a SAHPRA licensed pharmaceutical company with a number of local and international partners with a broad base of pharmaceutical products which address unmet medical needs. 3Sixty Biopharmaceuticals also has a respectable Clinical Research & Development (CR&D) pipeline of Small molecules, Peptides and Isotopes to address a spectrum of diseases. The company also has its own fully fledged Medical, Regulatory, Supply Chain, Finance and commercialisation team to drives to its commercial imperatives.
3Sixty Nuclear Medicine
We specialise in the captivating realm of nuclear medicine! As a highly specialised company, we harness the power of isotopes to develop targeted therapies for therapeutics, and the agnostics. Our unwavering commitment to enhancing lives drives our dedication to providing patients with innovative radiopharmaceutical therapies and treatments.
3Sixty Health
In 1978, 3Sixty Health, formerly Sechaba Medical Solutions, was founded by 38 black professionals, primarily doctors, with a mission to provide medical aid to disenfranchised black South Africans. Led by Dr. Nthato Motlana and visionaries like Dr. Abner Tlakula, they established Sechaba Medical Solutions and Sizwe Medical Fund. In 2019, Sechaba Medical Solutions rebranded as 3Sixty Health. Today, more than 40 years later, 3Sixty Health manages the amalgamated Sizwe Hosmed Medical Scheme and SAB Medical Scheme, serving over 70,000 principal members, remaining committed to providing accessible healthcare to all.
Cape Sativa Corporation
Cape Sativa is a subsidiary of 3Sixty Global Solutions Group, an integrated Biotechnology and Healthcare Group. Cape Sativa uses a patented Nano Technology Platform that makes cannabinoids more water soluble, and more stable, with enhanced cellular absorption, for application in pharmaceuticals, medicinals, nutraceuticals, cosmeceuticals, beverages, and edibles.
CDE
Larry Distiller, internationally renowned Endocrinologist and healthcare visionary founded the CDE (Centre for Diabetes and Endocrinology) in 1994. He yearned to bring quality care to all South African’s (and African’s) living with diabetes mellitus.
To do this, he created a holistic and comprehensive treatment and management programme, which promoted the implementation of evidence-based and person-centred diabetes care principles.
Thus, in 1995, the CDE ‘Diabetes Management Programme’ was born, and over succeeding decades it developed and expanded across CDE-affiliated private medical practices nationwide. This was ground-breaking stuff – at that time, the concept of managed healthcare was foreign in South Africa, and the idea of ring-fencing, capitating and managing a condition like diabetes was revolutionary.